Neuland Labs Q1FY25
Neuland unveils its dynamic new brand identity reinforcing
Neuland unveils refreshed brand identity
Neuland Laboratories Q4 FY24 Earnings Conference Call May 14, 2024
A Check-in on 2024 Trends in the CDMO Industry
Brokerage Goldman Sachs has initiated buy ratings on Syngene International Ltd and Neuland Laboratories Ltd and increased target price to Rs 875 (up 20 percent) and Rs 9100 (up 46 percent), respectively, from current market price. The brokerage house also initiated sell rating on Laurus Labs Ltd with a target price of Rs 350 a share, down 23 percent.
How to Ensure Effective Technology Transfer to CDMOs
Neuland Laboratories Ltd extended its gains and rose almost 6 percent after the company told the exchanges that the US Food and Drug Administration (FDA) completed an inspection in Hyderabad without any observations.
Neuland Labs Unit I Plant Passes USFDA Audit With Zero 483 Observations Again
Why Agility Matters When Choosing an API Contract Manufacturing Partner